Treatment methods

Abstract

The present invention is directed to the use of sterol absorption inhibiting compounds, pharmaceutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided.

1 - 47 . (canceled)  
     
     
         48 . A method of treating vascular disease comprising administering to a mammal in need of such treatment an effective amount of at least one treatment composition comprising an effective amount of at least one sterol absorption inhibitor or at least one stanol absorption inhibitor, or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or prodrug of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or mixture thereof to reduce plasma or tissue concentration of at least one non-cholesterol sterol, 5α-stanol or mixture thereof.  
     
     
         49 . A method of preventing or reducing arteriosclerosis comprising administering to a mammal in need of such treatment an effective amount of at least one treatment composition comprising an effective amount of at least one sterol absorption inhibitor or at least one stanol absorption inhibitor, or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or prodrug of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or mixture thereof to reduce plasma or tissue concentration of at least one non-cholesterol sterol, 5α-stanol or mixture thereof.  
     
     
         50 . A method of preventing or reducing atherosclerosis comprising administering to a mammal in need of such treatment an effective amount of at least one treatment composition comprising an effective amount of at least one sterol absorption inhibitor or at least one stanol absorption inhibitor, or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or prodrug of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or mixture thereof to reduce plasma or tissue concentration of at least one non-cholesterol sterol, 5α-stanol or mixture thereof.  
     
     
         51 . A method of preventing or reducing risk of a cardiovascular event selected from the group consisting of fatal acute major coronary events, non-fatal major coronary events, coronary revascularization procedures, peripheral vascular disease, stable angina and cerebrovascular insufficiency, comprising administering to a mammal an effective amount of at least one treatment composition comprising an effective amount of at least one sterol absorption inhibitor or at least one stanol absorption inhibitor, or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or prodrug of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or mixture thereof to reduce plasma or tissue concentration of at least one non-cholesterol sterol, 5α-stanol or mixture thereof.  
     
     
         52 . A method of preventing or reducing risk of a cardiovascular event selected from the group consisting of fatal acute major coronary events, non-fatal major coronary events, coronary revascularization procedures, peripheral vascular disease, stable angina and cerebrovascular insufficiency, comprising administering an effective amount of at least one treatment composition an effective amount of at least one sterol absorption inhibitor or at least one stanol absorption inhibitor, or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or prodrug of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor or pharmaceutically acceptable salt or solvate of the least one sterol absorption inhibitor or the at least one stanol absorption inhibitor, or mixture thereof to reduce plasma or tissue concentration of at least one non-cholesterol sterol, 5α-stanol or mixture thereof to a mammal having no history of clinically evident coronary heart disease prior to the initial administration.  
     
     
         53 - 58 . (canceled)